CMHC Newsletter

"The Monthly Beat"

CMHC monthly newsletters feature our most recent event & educational opportunities, with additional highlights including popular blog posts, podcast episodes, featured faculty members, and scientific spotlights.

HIGHLIGHT

Results of STEP trials with semaglutide 2.4mg for obesity management has experts excited about its potential

HIGHLIGHT

GALACTIC-HF shows that investigational agent omecamtiv mecarbil works best in heart failure patients with markedly reduced ejection fraction

HIGHLIGHT

American Heart Association releases new scientific statement on obesity and cardiovascular disease

HIGHLIGHT

Findings from the LOOK AHEAD study indicated that dyslipidemia was associated with a higher risk of CVD outcomes in large samples of obese individuals with T2DM

HIGHLIGHT

Entresto, a combination of sacubitril and valsartan, has been FDA approved to directly treat patients with heart failure (HF) with preserved ejection fraction (HFpEF)

HIGHLIGHT

Heart failure drug Vericiguat, an orally administered soluble guanylate cyclase (sGC) simulator, receives FDA approval

HIGHLIGHT

Happy New Year from the CMHC Team

HIGHLIGHT

Polypill with or without Aspirin in Persons without Cardiovascular Disease

HIGHLIGHT

FDA approves remdesivir as the first antiviral agent for COVID-19

HIGHLIGHT

Drug-Induced Arrhythmias: A Scientific Statement from the American Heart Association

HIGHLIGHT

Drug-Induced Arrhythmias: A Scientific Statement from the American Heart Association

HIGHLIGHT

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors

HIGHLIGHT

Research review article highlights the status of diabetes and its complications in Latin American population

HIGHLIGHT

FDA approves new treatment for HFrEF

HIGHLIGHT

New Recommendations for Diabetes Management & Other Hormone Disorders During COVID-19 Pandemic

HIGHLIGHT

Hydroxychloroquine-Azithromycin Treatment For COVID-19 May Pose a Risk for Ventricular Arrhythmia

HIGHLIGHT

FDA Approves Two Formulations of Bempedoic Acid for LDL-C Reduction

HIGHLIGHT

AHA Releases 2020 Heart Disease & Stroke Statistics Update

HIGHLIGHT

ADA Releases 2020 Standards of Medical Care in Diabetes

HIGHLIGHT

DAPA-HF Study Illustrates Safety and Efficacy of Dapagliflozin In Heart Failure

HIGHLIGHT

FDA Approves Dapagliflozin for Heart Failure in Type 2 Diabetes

HIGHLIGHT

FDA Expands Recall of Common Blood Pressure Drug

HIGHLIGHT

Type 2 Diabetes and Cardiac Remodeling

HIGHLIGHT

Study finds no link between SGLT-2 inhibitors and fracture risk in patients with type 2 diabetes

HIGHLIGHT

FDA Panel Leans Against Eliminating PAD Device Access

HIGHLIGHT

Weight Loss With Metformin Maintained at 15 Years

HIGHLIGHT

Harmful Medications Prescribed to Nearly 25% of Patients with HFrEF

HIGHLIGHT

REDUCE-IT Trial Presents Updated Findings

HIGHLIGHT

ACC & AHA will release comprehensive guidelines for primary CVD prevention at ACC conference

HIGHLIGHT

SCIENTIFIC SPOTLIGHT: Role of Real-World Data on Treatment of T2DM

HIGHLIGHT

NEWEST PROJECT: Prior Authorization for Access Resource Center

HIGHLIGHT

MOMENT WITH A MEMBER: Keith C. Ferdinand, MD, FACC, FAHA

HIGHLIGHT

BOSTON HIGHLIGHTS: Read Press Release

HIGHLIGHT

CLINICALLY CURRENT CME: Access Your Online Education

HIGHLIGHT

SCIENTIFIC SPOTLIGHT: Meta-Analysis Reports Aggressive LDL-C Lowering Reduces Cardiovascular Risk

HIGHLIGHT

EVENT ANNOUNCEMENTS: Small Group Workshops

HIGHLIGHT

POPULAR PODCAST: Joel Khan, MD

HIGHLIGHT

CLINICAL CASE CHALLENGE: Test Your Knowledge

HIGHLIGHT

FACULTY FORUM: CMHC faculty member Stephen Devries, MD

HIGHLIGHT

BEST BLOG: Fasting Diets Reduce Risk Factors For CVD

HIGHLIGHT

UPCOMING PROJECTS: The Cardiometabolic Chronicle

HIGHLIGHT

FEATURED ARTICLE: The Reality of Women and Cardiometabolic Disease
Industry Resources

See All Publications

Explore On Demand Content

Subscribe to "The Monthly Beat" Newsletter

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.

A division of Tarsus Medical owned by Tarsus Group
Connect

Cardiometabolic Health Congress
1801 N Military Trail, Ste 200
Boca Raton, FL, 33431

Copyright © 2021, Cardiometabolic Health Congress. All Rights Reserved.

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.